Ascelia Pharma
Biotechnology company developing and commercializing novel drugs for orphan oncology.
ACE | ST
Overview
Corporate Details
- ISIN(s):
- SE0010573113 (+2 more)
- LEI:
- 5493002YR9VCJJPWYN08
- Country:
- Sweden
- Address:
- Hyllie Boulevard 34, 215 32 Malmö
- Website:
- https://www.ascelia.com/
- Sector:
- Manufacturing
Description
Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-01-12 07:30 |
Ascelia Pharma presenterar klinisk utvecklingsplan för Oncoral som en ny cellgi…
|
Swedish | 204.6 KB | ||
| 2021-01-12 07:30 |
Ascelia Pharma presents clinical development plan for Oncoral as a novel chemot…
|
English | 202.0 KB | ||
| 2020-12-15 07:30 |
Ascelia Pharma gets US patent for second generation Mangoral
|
English | 190.6 KB | ||
| 2020-12-15 07:30 |
Ascelia Pharma får amerikanskt patent för andra generationens Mangoral
|
English | 190.6 KB | ||
| 2020-12-04 14:03 | English | 33.9 KB | |||
| 2020-12-02 08:00 |
Ny studie visar att Mangorals visualisering av lesioner är lika effektiv som ga…
|
Swedish | 217.8 KB | ||
| 2020-12-02 08:00 |
New study shows Mangoral’s lesion visualization as effective as gadolinium cont…
|
English | 192.3 KB | ||
| 2020-11-05 08:00 | Swedish | 1.0 MB | |||
| 2020-11-05 08:00 | English | 993.3 KB | |||
| 2020-10-21 08:00 |
Det uppskattade värdet på Mangorals marknadspotential höjs till 500-600 miljone…
|
Swedish | 211.2 KB | ||
| 2020-10-21 08:00 |
Upgraded estimate of addressable market for Mangoral to $500-600 million annual…
|
English | 213.5 KB | ||
| 2020-10-19 15:23 | English | 34.0 KB | |||
| 2020-08-20 08:00 | Swedish | 1.3 MB | |||
| 2020-08-20 08:00 | English | 1.1 MB | |||
| 2020-07-31 14:00 |
Change in number of shares and votes in Ascelia Pharma AB
|
English | 185.3 KB |
Automate Your Workflow. Get a real-time feed of all Ascelia Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Ascelia Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Ascelia Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-22 | Marie Birgitta Källström | Other | Other | 18,752 | 40,316.80 SEK |
| 2025-04-15 | Niels Mengel | Other | Other | 92,304 | 198,453.60 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 50,000 | 107,500.00 SEK |
| 2025-04-15 | Carin Linde | Other | Other | 40,328 | 86,705.20 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 21,688 | 46,629.20 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 20,472 | 44,014.80 SEK |
| 2025-04-15 | Julie Brogren | Other | Other | 18,000 | 38,700.00 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 6,152 | 13,226.80 SEK |
| 2024-09-03 | KIBEGEON | Other | Sell | 913,545 | 150,917.63 SEK |
| 2024-09-03 | Niels Mengel | Other | Sell | 131,965 | 17,815.28 SEK |
Peer Companies
